Growth hormone–releasing hormone (GHRH), also known as somatocrinin among other names in its endogenous form and as somatorelin (INN) in its pharmaceutical form, is a releasing hormone of growth hormone (GH). It is a 44 [1] - amino acid peptide hormone produced in the arcuate nucleus of the hypothalamus.

2005年7月1日 · Three maleimido derivates of human GH-releasing factor (hGRF) 1–29 were synthesized and bioconjugated to human serum albumin ex vivo. All three human serum albumin conjugates showed enhanced in vitro stability against dipeptidylpeptidase-IV and were bioactive in a GH secretion assay in cultured rat anterior pituitary cells.

We conclude that the optimal dose required to elicit maximum GH release with minimal unwanted effects is 80 micrograms in adults. These are related to the dose and observed for doses up to 80-150 micrograms. Subcutaneous administration also induced GH-release, with relationship to the doses used (100, 300 and 600 micrograms per subject).

1986年1月1日 · We conclude that the optimal dose required to elicit maximum GH release with minimal unwanted effects is 80 μg in adults. These are related to the dose and observed for doses up to 80–150 μg. Subcutaneous administration also induced GH-release, with relationship to the doses used (100, 300 and 600 μg per subject).

1986年1月1日 · 人类生长激素释放因子（hGRF）的最新可用性鼓励了对人类生长激素分泌的全面研究。 而且，现在有可能提出这种激素的治疗 应用。 在本文中，我们报告了在三种方案中，静脉内给予每名受试者2.5至600微克剂量的正常年轻男性中，hGRF和GH反应之间获得的剂量效应关系。 与安慰剂相比，在一些受试者中2.5微克剂量引起GH分泌。 在5至80微克的剂量范围内，观察到了非常显着的剂量效应（基于GH-AUC和GH-peak）。 80微克以上的反应是相同的。 我们得 …

Transgenic mice expressing the human growth hormone-releasing factor (hGRF) gene linked to the metallothionein promoter exhibit high circulating levels of hGRF and GH and increased growth.

2003年9月26日 · Growth hormone-releasing factor (GRF) is a secreted hypothalamic 44 amino acids peptide involved in the regulation of the expression and release of growth hormone (GH) from the anterior pituitary gland through a receptor-mediated mechanism [1], [2], [3].

Three ranges of doses of growth hormone releasing factor (2.5-80 micrograms, 80-320 micrograms and 75-600 micrograms) were intravenously administered to healthy young volunteers in three double blind studies. Serum circulating GRF levels were determined by radioimmunoassay.

1985年1月1日 · Solid phase peptide synthesis has been successfully applied to the preparation of GRF found in human hypothalamus (hGRF). A series of peptides structurally unrelated to the somatocrinins have also been discussed in the chapter to …

Three ranges of doses of growth hormone releasing factor (2.5–80 µg, 80–320 µg and 75–600 µg) were intravenously administered to healthy young volunteers in three double blind studies. Serum circulating GRF levels were determined by radioimmunoassay.